Annals of Military and Health Sciences Research

Published by: Kowsar
Crossmark

Serum Lysophosphatidic Acid as a Potential Biomarker of Prostate Cancer

Sadegh Amiri 1 , Beheshteh Abouhamzeh ORCID 1 , * , Iraj Mirzaii-Dizgah 2 , Seyed Reza Yahyazadeh 3 , Mohsen Sokounati 3 and Fatemeh Amiri 4
Authors Information
1 Department of Anatomical Sciences, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran
2 Department of Physiology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran
3 Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
4 Nursing and Midwifery Faculty, Iran University of Medical Sciences, Tehran, Iran
Article information
  • Annals of Military and Health Sciences Research: September 30, 2019, 17 (3); e95726
  • Published Online: August 13, 2019
  • Article Type: Research Article
  • Received: June 26, 2019
  • Revised: August 3, 2019
  • Accepted: August 3, 2019
  • DOI: 10.5812/amh.95726

How to Cite: Amiri S , Abouhamzeh B, Mirzaii-Dizgah I, Yahyazadeh S R, Sokounati M, et al. Serum Lysophosphatidic Acid as a Potential Biomarker of Prostate Cancer, Ann Mil Health Sci Res. 2019 ; 17(3):e95726. doi: 10.5812/amh.95726.

Abstract
Copyright © 2019, Annals of Military and Health Sciences Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. doi: 10.3322/caac.21262. [PubMed: 25651787].
  • 2. Wu PY, Lin YC, Huang YL, Chen WM, Chen CC, Lee H. Mechanisms of lysophosphatidic acid-mediated lymphangiogenesis in prostate cancer. Cancers (Basel). 2018;10(11). doi: 10.3390/cancers10110413. [PubMed: 30384405]. [PubMed Central: PMC6266502].
  • 3. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349(4):366-81. doi: 10.1056/NEJMra021562. [PubMed: 12878745].
  • 4. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res. 1995;1(10):1223-32. [PubMed: 9815916].
  • 5. Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev. 2010;62(4):579-87. doi: 10.1124/pr.110.003111. [PubMed: 21079037]. [PubMed Central: PMC2993255].
  • 6. Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, et al. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013;65(3):967-86. doi: 10.1124/pr.112.007179. [PubMed: 23686350]. [PubMed Central: PMC3698937].
  • 7. Abouhamzeh B, Mirzaii-Dizgah I, Ravaei A. Serum lysophosphatidic acid level in chronic myeloid leukemia. Ann Mil Health Sci Res. 2017;15(1). doi: 10.5812/amh.62801.
  • 8. Hao F, Tan M, Xu X, Han J, Miller DD, Tigyi G, et al. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha. Biochim Biophys Acta. 2007;1771(7):883-92. doi: 10.1016/j.bbalip.2007.04.010. [PubMed: 17531530]. [PubMed Central: PMC3446792].
  • 9. Guo R, Kasbohm EA, Arora P, Sample CJ, Baban B, Sud N, et al. Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology. 2006;147(10):4883-92. doi: 10.1210/en.2005-1635. [PubMed: 16809448].
  • 10. Gibbs TC, Xie Y, Meier KE. Regulation of expression of EDG family receptors in human prostate cancer cell lines. Ann N Y Acad Sci. 2000;905:290-3. doi: 10.1111/j.1749-6632.2000.tb06563.x. [PubMed: 10818467].
  • 11. Meleh M, Pozlep B, Mlakar A, Meden-Vrtovec H, Zupancic-Kralj L. Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;858(1-2):287-91. doi: 10.1016/j.jchromb.2007.08.008. [PubMed: 17766199].
  • 12. Ortlepp C, Steudel C, Heiderich C, Koch S, Jacobi A, Ryser M, et al. Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation. Exp Hematol. 2013;41(5):444-461 e4. doi: 10.1016/j.exphem.2013.01.007. [PubMed: 23377000].
  • 13. Castillejos-Molina RA, Gabilondo-Navarro FB. Prostate cancer. Salud Publica Mex. 2016;58(2):279-84. [PubMed: 27557386].
  • 14. Hao Y, Zhao Y, Zhao X, He C, Pang X, Wu TC, et al. Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling. Cancer Invest. 2011;29(4):318-24. doi: 10.3109/07357907.2011.554477. [PubMed: 21345070]. [PubMed Central: PMC3305797].
  • 15. Sirousbakht S, Rezakhaniha B. Effect of colonoscopy on prostate-specific antigen; new words about an old subject. Int J Canc Manag. 2018;11(7). doi: 10.5812/ijcm.68919.
  • 16. Ruiz-Garcia V, Juan O, Perez Hoyos S, Peiro R, Ramon N, Rosero MA, et al. [Megestrol acetate: A systematic review usefulness about the weight gain in neoplastic patients with cachexia]. Med Clin (Barc). 2002;119(5):166-70. Spanish. [PubMed: 12200017].
  • 17. Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89(6):2832-6. doi: 10.1210/jc.2003-031768. [PubMed: 15181065].
  • 18. Mariani L, Lo Vullo S, Bozzetti F; Scrinio Working Group. Weight loss in cancer patients: A plea for a better awareness of the issue. Support Care Cancer. 2012;20(2):301-9. doi: 10.1007/s00520-010-1075-7. [PubMed: 21210155].
  • 19. Panupinthu N, Lee HY, Mills GB. Lysophosphatidic acid production and action: Critical new players in breast cancer initiation and progression. Br J Cancer. 2010;102(6):941-6. doi: 10.1038/sj.bjc.6605588. [PubMed: 20234370]. [PubMed Central: PMC2844037].
  • 20. Li YY, Zhang WC, Zhang JL, Zheng CJ, Zhu H, Yu HM, et al. Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: A meta-analysis. Lipids Health Dis. 2015;14:72. doi: 10.1186/s12944-015-0071-9. [PubMed: 26174150]. [PubMed Central: PMC4501043].
  • 21. Liu Y, Burkhalter R, Symowicz J, Chaffin K, Ellerbroek S, Stack MS. Lysophosphatidic acid disrupts junctional integrity and epithelial cohesion in ovarian cancer cells. J Oncol. 2012;2012:501492. doi: 10.1155/2012/501492. [PubMed: 22593767]. [PubMed Central: PMC3346998].
  • 22. Yoon HR, Kim H, Cho SH. Quantitative analysis of acyl-lysophosphatidic acid in plasma using negative ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;788(1):85-92. [PubMed: 12668074].
  • 23. Meng Y, Kang S, So J, Reierstad S, Fishman DA. Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis. Gynecol Oncol. 2005;96(2):462-9. doi: 10.1016/j.ygyno.2004.10.024. [PubMed: 15661236].
  • 24. Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, et al. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res. 2006;66(5):2740-8. doi: 10.1158/0008-5472.CAN-05-2947. [PubMed: 16510595].
  • 25. Oyesanya RA, Lee ZP, Wu J, Chen J, Song Y, Mukherjee A, et al. Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells. FASEB J. 2008;22(8):2639-51. doi: 10.1096/fj.07-101428. [PubMed: 18362203]. [PubMed Central: PMC2493458].
  • 26. Hu X, Mendoza FJ, Sun J, Banerji V, Johnston JB, Gibson SB. Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies. Cell Signal. 2008;20(6):1198-208. doi: 10.1016/j.cellsig.2008.02.009. [PubMed: 18396013].
  • 27. Underiner TL, Ruggeri B, Gingrich DE. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr Med Chem. 2004;11(6):731-45. [PubMed: 15032727].
  • 28. Lee J, Park SY, Lee EK, Park CG, Chung HC, Rha SY, et al. Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clin Cancer Res. 2006;12(21):6351-8. doi: 10.1158/1078-0432.CCR-06-1252. [PubMed: 17085645].
  • 29. Kim KS, Sengupta S, Berk M, Kwak YG, Escobar PF, Belinson J, et al. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res. 2006;66(16):7983-90. doi: 10.1158/0008-5472.CAN-05-4381. [PubMed: 16912173].
  • 30. Do TV, Symowicz JC, Berman DM, Liotta LA, Petricoin EF 3rd, Stack MS, et al. Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. Mol Cancer Res. 2007;5(2):121-31. doi: 10.1158/1541-7786.MCR-06-0319. [PubMed: 17314270].
  • 31. Bian D, Su S, Mahanivong C, Cheng RK, Han Q, Pan ZK, et al. Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK Kinase 1 pathway. Cancer Res. 2004;64(12):4209-17. doi: 10.1158/0008-5472.CAN-04-0060. [PubMed: 15205333].
  • 32. Rusovici R, Ghaleb A, Shim H, Yang VW, Yun CC. Lysophosphatidic acid prevents apoptosis of Caco-2 colon cancer cells via activation of mitogen-activated protein kinase and phosphorylation of Bad. Biochim Biophys Acta. 2007;1770(8):1194-203. doi: 10.1016/j.bbagen.2007.04.008. [PubMed: 17544220]. [PubMed Central: PMC1989128].
  • 33. Kim MH, Park JS, Chang HJ, Baek MK, Kim HR, Shin BA, et al. Lysophosphatidic acid promotes cell invasion by up-regulating the urokinase-type plasminogen activator receptor in human gastric cancer cells. J Cell Biochem. 2008;104(3):1102-12. doi: 10.1002/jcb.21696. [PubMed: 18247343].
  • 34. Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta. 2008;1781(9):513-8. doi: 10.1016/j.bbalip.2008.06.005. [PubMed: 18621144].
  • 35. Pages C, Simon MF, Valet P, Saulnier-Blache JS. Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat. 2001;64(1-4):1-10. [PubMed: 11324699].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments